Drilldown: Medicines
Medicines > classes 
:
Analgesic or
[[:Category:Overactive_bladder_medications|Overactive bladder medication]]
:
Analgesic or
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] Use the filters below to narrow your results.
generic:
Buprenorphine (1) ·
Butorphanol (1) ·
Codeine (2) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Levorphanol (1) ·
Meperidine (1) ·
Methadone (1) ·
Mirabegron (1) ·
Nalbuphine (1) ·
Oxybutynin (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Solifenacin (1) ·
Tapentadol (1)
brand:
None (5) ·
(multiple, generic dominant) (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Ditropan, Ditropan XL, Oxytrol (transdermal), Gelnique (gel) (1) ·
Dolophine (1) ·
Duragesic (1) ·
Myrbetriq (1) ·
Nubain (1) ·
Nucynta (1) ·
Opana (1) ·
Stadol (1) ·
Suboxone (1) ·
Talwin (1) ·
Vesicare (1) ·
Vicodin (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
'"`UNIQ--vote-00000DFA-QINU`"' CYP3A4 substrate; QT-interval prolongation has been reported at higher doses. Like other antimuscarinics, contributes to cumulative anticholinergic burden in older adults'"`UNIQ--ref-00000DFB-QINU`"'. (1)
uses:
None (17) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"' (1) ·
'"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1) ·
'"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"' (1)
starting dose:
preparations:
None (17) ·
25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) ·
5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel (1) ·
5, 10 mg tablets (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (17) ·
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1) ·
~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1)
pregnancy:
Showing below up to 21 results in range #1 to #21.